Myopathy induced by clofibrate treatment in normolipaemic patients.
On the basis of the occurrence of myopathy in a clofibric acid treated child with diabetes insipidus, three other children with the same diseases were examined in order to find indications for a myopathic side-effect of the drug. When the children were found to have increased creatine phosphokinase activity and EMG changes, two of the authors took clofibric acid themselves. In both test persons subclinical myopathy was produced. After stopping the drug, transitional hypertriglyceridaemia occurred. These side-effects should serve as a warning of an uncritical application of clofibric acid and its esters.
D002648:Child; D002994:Clofibrate / Q000009:adverse effects* / Q000378:metabolism; D003402:Creatine Kinase / Q000097:blood; D003919:Diabetes Insipidus / Q000188:drug therapy* / Q000201:enzymology; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008055:Lipids / Q000097:blood; D008297:Male; D009135:Muscular Diseases / Q000139:chemically induced* / Q000201:enzymology
D008055:Lipids; D003402:Creatine Kinase; D002994:Clofibrate